For 60 years, the iF product design award has been a coveted and internationally recognised label for award-winning design and the iF brand has become a symbol for outstanding achievement in design.
DCA are delighted to announce that the new pen injector for Sanofi's GLP-1 medication, Lyxumia®, has won an iF product design award 2013 and will be recognised with the prestigious iF label. This adds to a Chicago Athenaeum Good Design award win for the Lyxumia® pen in December 2012.
The iF design awards night took centre stage at the BMW World auditorium, on 22nd February, as part of the Munich Creative Business Week. After the official award ceremony, the DCA and Sanofi teams together with other winners and guests from the areas of design, business, culture, politics and the media, celebrated the award wins.
DCA Managing Director, Rob Woolston said 'we had a great time celebrating this win with our colleagues from Sanofi and we are extremely pleased that this distinctive design, which was only launched this year, has already won these major awards.'
A recent press release from Sanofi states: 'With the European approval of Lyxumia®, we now have a simple new tool to help patients with type 2 diabetes further reduce HbA1c, with the benefit of weight loss and limited risk of hypoglycaemia. This well-tolerated therapy is of specific interest to patients who are on oral treatments and/or basal insulin and do not manage to maintain their HbA1c targets. With a single daily injection and only one step to maintenance dose, Lyxumia® is a positive addition to the Sanofi portfolio, and represents another step forward in our efforts to advance scientific excellence and develop new therapeutic solutions that improve outcomes for people with diabetes.'
(Lyxumia® is a registered brand of Sanofi Aventis).
